ArticleMMWR. Morbidity and mortality weekly report2015
Launch of a Nationwide Hepatitis C Elimination Program--Georgia, April 2015.
Article in MMWR. Morbidity and mortality weekly report, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 109 citations in OpenAlex.
- Directly observed therapy of sofosbuvir/ribavirin +/- peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT).Journal of viral hepatitis · 2018Trial
- Incidence of and Risk Factors for Tuberculosis Among Patients Treated for Hepatitis C: a Population-based Cohort Study.Open forum infectious diseases · 2026Article
- Achieving Hepatitis C Micro-Elimination in a High-Burden Province of Thailand: The Phetchabun Model.Tropical medicine and infectious disease · 2026Article
- Results of the HCV self-testing implementation study through the secondary distribution of HCV self-tests among adult males in Georgia.BMC public health · 2026Observational
- Primary liver cancer in Georgia: Seven years' experience following the launch of the Hepatitis C Elimination Program, 2015-2022.PloS one · 2026Article
- Hospital-based micro-elimination of hepatitis C virus: improving timely case identification and linkage to care in a tertiary hospital.Frontiers in medicine · 2026Article
- Demographic and Clinical Characteristics of Patients With Hepatitis C and Hepatitis B Co-Infection, Georgia, 2017-2023.Journal of viral hepatitis · 2025Article
- Temporal trends in hepatitis C incidence among people tested more than once in Georgia, 2017-23: a nationwide, retrospective cohort.The lancet. Gastroenterology & hepatology · 2025Article
- Evaluation of Hepatitis C Virus Transmission Through Endoscopy Procedures in the Country of Georgia.Journal of viral hepatitis · 2025Article
- Trends in new hepatitis C virus infections among repeat blood donors - Georgia, 2017-2023.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2025Article
- HIV and hepatitis C Virus in internally displaced people with and without injection drug use experience in the region of Shida Kartli, Georgia.BMC research notes · 2024Article
- Hepatitis C virus attributable liver cancer in the country of Georgia, 2015-2019: a case-control study.BMC infectious diseases · 2024Article
- Nationwide Hepatitis C Serosurvey and Progress Towards Hepatitis C Virus Elimination in the Country of Georgia, 2021.The Journal of infectious diseases · 2023Article
- Impact of Hepatitis C Virus Infection and Treatment on Mortality in the Country of Georgia, 2015-2020.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Advancing blood transfusion safety using molecular detection in the country of Georgia.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2023Article
- Hepatitis C care cascade among patients with and without tuberculosis: Nationwide observational cohort study in the country of Georgia, 2015-2020.PLoS medicine · 2023Observational
- The care cascade for hepatitis C virus and prognosis of chronic hepatitis C patients treated with antiviral agents in a tertiary hospital.BMC gastroenterology · 2023Article
- Economic evaluation of the Hepatitis C virus elimination program in the country of Georgia, 2015 to 2017.Liver international : official journal of the International Association for the Study of the Liver · 2023Article
- Association of Treated and Untreated Chronic Hepatitis C With the Incidence of Active Tuberculosis Disease: A Population-Based Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Treatment of hepatitis C in primary health care in the country of Georgia.Clinical liver disease · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
20 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) infects an estimated 130-150 million persons globally and results in an estimated 700,000 deaths annually from hepatocellular carcinoma or cirrhosis. Georgia, a middle-income Eurasian country, has one of the highest estimated HCV prevalences in the world. In 2011, Georgia began offering treatment to a limited number of HCV-infected persons. Beginning in 2013, when new oral medications that can cure >90% of HCV infections were licensed, Georgia engaged partners to develop a comprehensive HCV prevention and control plan, during which the concept of elimination of HCV transmission and disease emerged. To prepare for the launch of an HCV elimination program, Georgia requested CDC's assistance to describe HCV epidemiology, evaluate laboratory and health care capacity, and conduct program monitoring and evaluation. This report describes the activities undertaken to prepare for the program, launched in April 2015, and early results of its initial phase, focused on improving access to affordable diagnostics and free curative treatment for HCV-infected persons with severe liver disease. A national population-based serosurvey began in May 2015, and four clinical sites and their laboratories were selected as initial pilot sites; since June, three additional sites have been added. Through July 3, 2015, a total of 6,491 persons sought treatment, and 6,177 (95.2%) initiated diagnostic work-up. Among these, 1,519 (24.6%) completed work-up, 1,474 (97.0%) of whom initiated treatment. Georgia is scaling up capacity to meet the demand for HCV treatment and is collaborating with CDC and other partners on development of a comprehensive HCV elimination plan that includes specific goals and activities needed to achieve them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.